Indivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence

SLOUGH, England and RICHMOND, Va., May 25, 2018 -- (Healthcare Sales & Marketing Network) -- Indivior PLC (LON: INDV) today announced that it has filed a regulatory submission with Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE™ (bupreno... Biopharmaceuticals, Drug Delivery, Regulatory Indivior, SUBLOCADE, buprenorphine, opioid use disorder
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news